Carlo Allegri / Reuters Theranos, the disgraced blood testing commercial enterprise, is in dire financial straits and might need to default on a $100 million loan, according to a letter to shareholders from its CEO Elizabeth Holmes that became into obtained via BuzzFeed Tips.In the look at, sent to merchants Tuesday, the embattled Theranos founder pointed out that the commercial enterprise had hit delays on a blood seem to be at a number of for the Zika virus and had been unable to obtain approval for the product from the Ingredients and Drug Administration. It moreover requested its latest merchants for more dollars.FDA approval was crucial for the commercial enterprise to unlock a tranche of debt funding from private equity business Fortress Investment Group, which in December agreed to loan Theranos $100 million, but in installments and upon the success of particular milestones.Up until Tuesday, the commercial enterprise had only received $65 million of that dedication from Fortress, wrote Holmes, who pointed out she requested Fortress if it could unencumber the next $10 million tranche devoid of the FDA approval for the seem to be at a number of. That became into not assured, according to Holmes, who then described that to reduce bills, all besides the fact that children a handful of personnel had been notified that they’d be laid off interior 60 days. The Wall Highway Journal first mentioned on these layoffs and pointed out that headcount would be diminished from 100 twenty fi personnel to below two dozen.“These tendencies go away the commercial enterprise in a tough ,” Holmes wrote, noting that an lack of skill to secure extra financing may come to be in Theranos defaulting on its credit score contract with Fortress. A default could cause Theranos advertising off its assets in a foreclosures sale to fulfill its initiatives to the private equity business.Theranos’ poor financial health and its layoffs are the most up-to-date low in extra than a year of them for Holmes, who nonetheless has now now not admitted any wrongdoing for her feature in misleading the regular public, business companions, and merchants on the viability of her commercial enterprise’s blood tests. Last month, she settled civil fraud costs with the Securities and Trade Price, relinquishing voting control over her commercial enterprise, returning a huge part of Theranos shares, and agreeing to pay a $500,000 penalty. She still remains below investigation for advantage criminal costs during the US attorney’s place of work in San Francisco, according to the Journal, which first broke stories with regard to the commercial enterprise’s troubles in late 2015.Theranos did not instantly return a request for observation.In her letter, Holmes pointed out that the small group of personnel who will live after June eleven, “will consist very nearly of financial, legal and administrative personnel alongside a core technical crew, who will commit their efforts towards producing the highest shut-term return possible for our stakeholders” through a sale. That may additionally not happen, she warned, given the situations placed on the commercial enterprise via Fortress, which requires the commercial enterprise to have superior than $3 million in funds reserves, a examine that Holmes pointed out she expects the commercial enterprise to fall beneath during the conclusion of July even with the layoffs. When that occurs, Fortress would have the option to take full control of the commercial enterprise’s assets.Holmes moreover disclosed that in a foreclosures sale Fortress would doubtless be entitled to a 300% return on its investment sooner than different merchants were paid out. To stave off that opportunity, she raised the opportunity of her old backers, who have already put superior than $700 million into Theranos, investing additional.“The most viable alternative that we have diagnosed to avert an in depth-term sale or a likely default below our credit score contract is extra funding via one or additional of you,” she wrote. “In convenient of the place we’re, this is no easy ask. However, given your e-book of the commercial enterprise during the years, we favored to deliver this chance sooner than we proceed too a methods down the latest route.”Despite the commercial enterprise’s precipitous fall, Holmes revealed inside the look at that she nonetheless has some hope. Theranos has 1,175 granted or pending patents all over the world and earned a California company’s license in late 2017. Theranos, she pointed out, has moreover engaged a financial auditor to entire an audit of 2017 financials during the conclusion of June.“We recognize that the inventive and prescient of allotted laboratory sorting out is what impressed a lot of you to make investments, and we strongly believe that carrying on with our work in opposition t that conclusion could raise the shut-term charge of the commercial enterprise, and may deliver the groundwork for building huge prolonged-term charge,” she wrote.Read Elizabeth Holmes’ full letter to Theranos shareholders underneath April 10, 2018Dear Theranos Stockholders,We most excellent wrote on December 22, 2017, shortly after closing a secured debt financing transaction with Fortress Investment Group. We pointed out that the transaction provided us runway to proceed work on the miniLab and to location the commercial enterprise for additional financing activities—but outlined the slim route forward.Unfortunately, we are in the again of time desk on our first product milestone below the Fortress loan, and subsequently will fast face a funds shortage. Below we aspect our , apprise you of our options, and ask for your help as we proceed to work to realize charge in your investments. As we describe underneath, we are evaluating parallel paths, including advantage funding phrases that may provide a huge stake in the commercial enterprise at what we believe to be a very good charge.*****The Fortress financing, which closed on December eleven, 2017, provided Theranos with as a lot as $100 million of liquidity, subject to product and operational milestones. The first funding tranche of $65 million gross turned into launched at closing. The free up of a 2nd tranche of $10 million gross became into contingent upon FDA approval or CE marking of the Zika assay for use on the miniLab. Achieving that milestone interior the first zero.5 of 2018 was crucial to our marketing method.Development of the Zika assay has taken longer than envisioned. While the miniLab hardware and software have superior steadily considering the fact that that we most excellent wrote, we proceed to face issues with the reliability of the Zika assay chemistry itself. As a influence, timing for finalization of our FDA submission is still dubious. We have raised with Fortress the opportunity of releasing the 2nd tranche of funding inspite of the shortcoming of regulatory approval, but its willingness to obtain here’s not assured and we take note of that in any journey it goes to likely depend on our securing additional commitments from our latest merchants.These tendencies go away the commercial enterprise in a tough . Taking into consideration the enormous can cost-cutting measures we’re imposing at the present time, including the bargain in pressure described underneath, our greatest latest projections element out that—absent extra funding—our funds reserves will during the conclusion of July fall underneath the $3 million minimal liquidity threshold required during the Fortress loan. Under the phrases of our credit score contract with Fortress, our failure to preserve this minimal liquidity would signify an journey of default. Such an journey of default, or other activities of default that may additionally accompany the commercial enterprise’s decreased liquidity, could precipitate an exercise of treatments via Fortress, including Fortress’ taking full control of our assets to satisfy the commercial enterprise’s initiatives to Fortress. We predict that route would negatively have an affect on the portions, if any, available for distribution to our stockholders.To avoid or extend a default below our credit score contract, we intend to take each and every step we are in a position to to keep our closing capital. Accordingly, today we provided find, consistent with the WARN Act and other critical legislations, to all besides the fact that children a small group of personnel that their jobs will terminate in 60 days, on June eleven, 2018. Difficult despite the fact that that movement is, we estimate that the linked can charge bargain charges will help hold capital sufficient to fund our operations through in regards to the conclusion of July, without default below our credit score contract. After June eleven, our final personnel will consist very nearly of financial, legal and administrative personnel alongside a core technical crew, who will commit their efforts towards producing the highest shut-term return possible for our stakeholders, likely by the use of a sale of the commercial enterprise or its assets.The most viable alternative that we have diagnosed to avert an in depth-term sale or a likely default below our credit score contract is extra funding via one or additional of you. In convenient of the place we’re, this is no easy ask. However, given your e-book of the commercial enterprise during the years, we favored to deliver this chance sooner than we proceed too a methods down the latest route.Of course, even with new capital, the way ahead for the commercial enterprise would stay particularly dubious. Nevertheless, additional funding may consist of some meaningful benefits. A extra funding could help give insurance policy to your latest one by that includes the commercial enterprise time to continue developing the miniLab and/or to monetize its patent portfolio (subject to the phrases and must haves of the Fortress loan). Further funding might also also help us to avoid a sale for an uncertain volume—including a foreclosures sale following a liquidity-based default below the Fortress loan. Any such sale may enormously diminish the web realizable charge of our assets. Moreover, in particular eventualities, Fortress can be entitled to control a foreclosures sale and/or monetization of the assets and to realize as much as a three-times return on its funding (including, in addition to the portions loaned via Fortress, the expenses linked to Fortress’ monetization of the commercial enterprise’s assets). As a influence, those eventualities would severely cut again or get rid of any prospect of distributions to the commercial enterprise’s shareholders.Our patent portfolio—which provided substantial e-book for the Fortress financing—contains superior than 1,175 granted or pending patents foreign. We believe our patents cowl broad and significant utilized sciences, including: (i) the core technologies inside the miniLab; (ii) technologies underlying element-of-care devices at this time accessible available on the market and producing sizable earnings; and (iii) still-emerging utilized sciences, such as an ingestible digital sensor that recently received regulatory approval for use in monitoring medication compliance. We also believe these patents have the advantage not easiest to eventually give insurance policy to the miniLab, should it pay money for FDA regulatory approvals, on the market, but moreover to e-book a licensing campaign that might also generate significant additional revenues.We have precise improvement to assemble on. Having rebuilt our quality machine and utilized method-oriented safeguards for development and manufacturing, late most excellent yr we’ve been granted a California Company’s License following an audit of our manufacturing facilities. Last month, representatives of a 1/3-party notified physique carried out an audit of our Quality Machine; we take note of that the auditors will imply issuance of the ISO 13485:2016 and MDSAP (Medical Machine Single Audit Software) certification for the Theranos Quality Machine. We have moreover engaged a financial auditor, which expects to entire work on an audit of our 2017 financials during the conclusion of June.We recognize that the inventive and prescient of allotted laboratory sorting out is what impressed a lot of you to make investments, and we strongly believe that carrying on with our work in opposition t that conclusion could raise the shut-term charge of the commercial enterprise, and may deliver the groundwork for building huge prolonged-term charge.Although now not however set, the funding phrases we are pondering would provide a huge stake in the commercial enterprise at a very good charge, in convenient of what we estimate is the intrinsic charge of the commercial enterprise’s assets. We predict that new funding would take the diversity of a senior class of favourite stock, which would moreover function huge governance rights, allowing participating investors a huge feature in steering the enterprise forward.Please look at that if we latest new equity securities at a price per share below the critical conversion charge of our latest sequence of favourite stock, the ensuing anti-dilution alterations might also cause huge dilution to our latest stockholders. Such an presenting would viable require the consent of the holders of a majority of our latest Sequence C-1B and Sequence C-2A Favourite Stock. The activities of these stockholders, who are senior to all other classes and sequence of stock with admire to expense upon a liquidation or deemed liquidation of the commercial enterprise, may fluctuate from holders of other classes or sequence of our stock. Holders of Sequence C-1B and Sequence C-2A Favourite Inventory have to even be mindful that their failure to take half in a financing having a purchase order order charge of below $5 per share would influence in necessary conversion of their shares into nonvoting Sequence C-1B* or Sequence C-2A* Preferred Stock.Subject to our compliance with the preemptive rights of particular merchants, we will latest this likelihood to all stockholders who are accepted investors interior the meaning of Rule 501(a) under the Exchange Act of 1933, as amended. For any accepted investor who is drawn to exploring it, we can deliver a time duration sheet and may be discovered to fulfill at any time. Irrespective of your future funding intent, we charge your engagement as stockholders and welcome your questions and remarks.*****This letter and its contents are non-public. We request that you simply now now not share or discuss this letter with others, except your attorneys, accountants and distinctive advisors bound via confidentiality initiatives. The unauthorized disclosure of this letter might also violate the phrases of agreements between you and the commercial enterprise, and may additionally depress the volume realizable upon a sale of our assets. This letter shall now now not constitute a tenet to advertise or the solicitation of a tenet to buy securities, nor shall there be any sale of our securities in any state or jurisdiction in which such latest, solicitation or sale can be unlawful old to registration or qualification below the securities felony instructions of this classification of state or jurisdiction or a sound exemption therefrom. Any presenting that we conduct can be made easiest to accepted merchants and easiest pursuant to definitive offering data, including a disclosure gear.Thank you once once again for your e-book.THERANOS, INC.Elizabeth HolmesChairman and CEO

Likes

Posted on: April 13, 2018

Posted by:

img

Carlo Allegri / Reuters

Theranos, the disgraced blood testing company, is in dire financial straits and may have to default on a $100 million loan, according to a letter to shareholders from its CEO Elizabeth Holmes that was obtained by BuzzFeed News.

In the note, sent to investors Tuesday, the embattled Theranos founder said that the company had hit delays on a blood test for the Zika virus and had been unable to obtain approval for the product from the Food and Drug Administration. It also asked its existing investors for more money.

FDA approval was necessary for the company to unlock a tranche of debt funding from private equity firm Fortress Investment Group, which in December agreed to loan Theranos $100 million, but in installments and upon the achievement of certain milestones.

Up until Tuesday, the company had only received $65 million of that commitment from Fortress, wrote Holmes, who said she asked Fortress if it would release the next $10 million tranche without the FDA approval for the test. That was not assured, according to Holmes, who then explained that to cut costs, all but a handful of employees had been notified that they would be laid off within 60 days. The Wall Street Journal first reported on those layoffs and said that headcount would be reduced from 125 employees to less than two dozen.

“These developments leave the company in a difficult situation,” Holmes wrote, noting that an inability to secure further financing may result in Theranos defaulting on its credit agreement with Fortress. A default may lead to Theranos selling off its assets in a foreclosure sale to fulfill its obligations to the private equity firm.

Theranos’ poor financial health and its layoffs are the latest low in more than a year of them for Holmes, who still has not admitted any wrongdoing for her role in misleading the public, business partners, and investors on the viability of her company’s blood tests. Last month, she settled civil fraud charges with the Securities and Exchange Commission, relinquishing voting control over her company, returning a large portion of Theranos shares, and agreeing to pay a $500,000 penalty. She still remains under investigation for potential criminal charges by the US attorney’s office in San Francisco, according to the Journal, which first broke stories about the company’s troubles in late 2015.

Theranos did not immediately return a request for comment.

In her letter, Holmes said that the small group of employees who will remain after June 11, “will consist primarily of financial, legal and administrative personnel alongside a core technical team, who will dedicate their efforts toward generating the maximum near-term return achievable for our stakeholders” through a sale. That may not happen, she warned, given the conditions placed on the company by Fortress, which requires the company to have more than $3 million in cash reserves, a figure that Holmes said she expects the company to fall below by the end of July even with the layoffs. When that occurs, Fortress would have the option to take full control of the company’s assets.

Holmes also disclosed that in a foreclosure sale Fortress would possibly be entitled to a 300% return on its investment before other investors were paid out. To stave off that possibility, she raised the possibility of her past backers, who have already put more than $700 million into Theranos, investing more.

“The most viable option that we have identified to forestall a near-term sale or a potential default under our credit agreement is further investment by one or more of you,” she wrote. “In light of where we are, this is no easy ask. However, given your support of the company over the years, we wanted to provide this opportunity before we proceed too far down the current path.”

Despite the company’s precipitous fall, Holmes revealed in the note that she still has some hope. Theranos has 1,175 granted or pending patents around the world and earned a California manufacturer’s license in late 2017. Theranos, she said, has also engaged a financial auditor to complete an audit of 2017 financials by the end of June.

“We recognize that the vision of distributed laboratory testing is what inspired many of you to invest, and we strongly believe that continuing our work toward that end could increase the near-term value of the company, and could provide the basis for building significant long-term value,” she wrote.

Read Elizabeth Holmes’ full letter to Theranos shareholders below

April 10, 2018

Dear Theranos Stockholders,


We last wrote on December 22, 2017, shortly after closing a secured debt financing transaction with Fortress Investment Group. We said that the transaction provided us runway to continue work on the miniLab and to position the company for additional financing events—but acknowledged the narrow path forward.


Unfortunately, we are behind schedule on our first product milestone under the Fortress loan, and as a result will soon face a cash shortage. Below we detail our situation, apprise you of our options, and ask for your help as we continue to work to realize value for your investments. As we describe below, we are evaluating parallel paths, including potential investment terms that would provide a large stake in the company at what we believe to be a favorable price.


*****


The Fortress financing, which closed on December 11, 2017, provided Theranos with up to $100 million of liquidity, subject to product and operational milestones. The first funding tranche of $65 million gross was released at closing. The release of a second tranche of $10 million gross was contingent upon FDA approval or CE marking of the Zika assay for use on the miniLab. Achieving that milestone within the first half of 2018 was crucial to our business plan.


Development of the Zika assay has taken longer than anticipated. While the miniLab hardware and software have progressed steadily since we last wrote, we continue to face issues with the reliability of the Zika assay chemistry itself. As a result, timing for finalization of our FDA submission remains uncertain. We have raised with Fortress the possibility of releasing the second tranche of funding despite the lack of regulatory approval, but its willingness to do so is not assured and we understand that in any event it will likely depend on our securing additional commitments from our existing investors.


These developments leave the company in a difficult situation. Taking into account the substantial cost-cutting measures we are implementing today, including the reduction in force described below, our best current projections indicate that—absent further funding—our cash reserves will by the end of July fall below the $3 million minimum liquidity threshold required by the Fortress loan. Under the terms of our credit agreement with Fortress, our failure to maintain this minimum liquidity would constitute an event of default. Such an event of default, or other events of default that may accompany the company’s decreased liquidity, could precipitate an exercise of remedies by Fortress, including Fortress’ taking full control of our assets to satisfy the company’s obligations to Fortress. We expect that path would negatively impact the amounts, if any, available for distribution to our stockholders.


To avoid or delay a default under our credit agreement, we intend to take every step we can to preserve our remaining capital. Accordingly, today we provided notice, consistent with the WARN Act and other applicable law, to all but a small group of employees that their jobs will terminate in 60 days, on June 11, 2018. Difficult though that action is, we estimate that the associated cost savings will help conserve capital sufficient to fund our operations through approximately the end of July, without default under our credit agreement. After June 11, our remaining staff will consist primarily of financial, legal and administrative personnel alongside a core technical team, who will dedicate their efforts toward generating the maximum near-term return achievable for our stakeholders, likely through a sale of the company or its assets.


The most viable option that we have identified to forestall a near-term sale or a potential default under our credit agreement is further investment by one or more of you. In light of where we are, this is no easy ask. However, given your support of the company over the years, we wanted to provide this opportunity before we proceed too far down the current path.


Of course, even with new capital, the future of the company would remain highly uncertain. Nevertheless, additional investment may come with some meaningful benefits. A further investment could help protect your current one by providing the company time to continue developing the miniLab and/or to monetize its patent portfolio (subject to the terms and conditions of the Fortress loan). Further investment could also help us to avoid a sale for an uncertain amount—including a foreclosure sale following a liquidity-based default under the Fortress loan. Any such sale could significantly diminish the net realizable value of our assets. Moreover, in certain scenarios, Fortress would be entitled to control a foreclosure sale and/or monetization of the assets and to realize up to a three-times return on its investment (including, in addition to the amounts loaned by Fortress, the costs associated with Fortress’ monetization of the company’s assets). As a result, those scenarios would significantly reduce or eliminate any prospect of distributions to the company’s shareholders.


Our patent portfolio—which provided substantial support for the Fortress financing—contains more than 1,175 granted or pending patents worldwide. We believe our patents cover broad and important technologies, including: (i) the core technologies in the miniLab; (ii) technologies underlying point-of-care devices currently on the market and generating sizable revenue; and (iii) still-emerging technologies, such as an ingestible digital sensor that recently received regulatory approval for use in monitoring medication compliance. We also believe these patents have the potential not only to eventually protect the miniLab, should it receive FDA regulatory approvals, on the market, but also to support a licensing campaign that could generate significant additional revenues.


We have real progress to build on. Having rebuilt our quality system and implemented process-oriented safeguards for development and manufacturing, late last year we were granted a California Manufacturer’s License following an audit of our manufacturing facilities. Last month, representatives of a third-party notified body conducted an audit of our Quality System; we understand that the auditors will recommend issuance of the ISO 13485:2016 and MDSAP (Medical Device Single Audit Program) certification for the Theranos Quality System. We have also engaged a financial auditor, which expects to complete work on an audit of our 2017 financials by the end of June.


We recognize that the vision of distributed laboratory testing is what inspired many of you to invest, and we strongly believe that continuing our work toward that end could increase the near-term value of the company, and could provide the basis for building significant long-term value.


Although not yet set, the investment terms we are considering would provide a large stake in the company at a favorable price, in light of what we estimate is the intrinsic value of the company’s assets. We expect that new investment would take the form of a senior class of preferred stock, which would also feature substantial governance rights, allowing participating investors a significant role in steering the company forward.


Please note that if we offer new equity securities at a price per share less than the applicable conversion price of our existing series of preferred stock, the resulting anti-dilution adjustments could cause significant dilution to our existing stockholders. Such an offering would likely require the consent of the holders of a majority of our existing Series C-1B and Series C-2A Preferred Stock. The interests of these stockholders, who are senior to all other classes and series of stock with respect to payment upon a liquidation or deemed liquidation of the company, may differ from holders of other classes or series of our stock. Holders of Series C-1B and Series C-2A Preferred Stock should also be aware that their failure to participate in a financing having a purchase price of less than $5 per share would result in mandatory conversion of their shares into nonvoting Series C-1B* or Series C-2A* Preferred Stock.


Subject to our compliance with the preemptive rights of certain investors, we will offer this opportunity to all stockholders who are accredited investors within the meaning of Rule 501(a) under the Exchange Act of 1933, as amended. For any accredited investor who is interested in exploring it, we can provide a term sheet and are available to meet at any time. Irrespective of your future investment intent, we value your engagement as stockholders and welcome your questions and comments.


*****


This letter and its contents are confidential. We request that you not share or discuss this letter with others, except your attorneys, accountants and other advisors bound by confidentiality obligations. The unauthorized disclosure of this letter could violate the terms of agreements between you and the company, and could additionally depress the amount realizable upon a sale of our assets. This letter shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction or a valid exemption therefrom. Any offering that we conduct will be made only to accredited investors and only pursuant to definitive offering documents, including a disclosure package.


Thank you again for your support.


THERANOS, INC.

Elizabeth Holmes

Chairman and CEO


Read More

Related Products to this Post

Related Posts